Health
VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms – TCTMD
Whether the benefit-risk balance is favorable depends on many factors, but it will be so “in very many cases,” the researcher says.
Venous thromboembolic (VTE) events are indeed increased after people get the COVID-19 vaccine from Oxford/AstraZeneca, but the absolute risk is low considering the proven effectiveness of vaccination and the continued spread of SARS-CoV-2 around the globe, researchers report in the BMJ.
After vaccination programs got underway, spontaneous reports of thrombotic events in people who had received the vaccine started coming in, with several European countries pausing its use in March due to the clots….
-
Business22 hours ago3 ASX ETFs to buy now for explosive long-term growth
-
Noosa News20 hours agoUp $136k in a year: Brisbane house price surges as Qld booms
-
Noosa News15 hours agoDicky Bill salad greens farms enter administration with 180 job cuts just before Christmas
-
General23 hours agoDeath toll in Hong Kong blaze rises to 146 after more bodies found